1700022I11Rik Activators
The term 1700022I11Rik Activators refers to a group of chemical agents identified by their role in promoting the activity of the 1700022I11Rik gene within the mouse genome. This gene's protein or RNA product is essential for certain cellular processes, and increasing its expression can influence the biological pathways in which it participates. The journey to discovering these activators typically commences with high-throughput screening, a process that tests a vast library of chemicals to find those that can enhance the gene's activity. This process often employs a reporter gene assay, where the promoter of 1700022I11Rik is linked to a luciferase reporter gene. Activation by a compound leads to an increase in luciferase expression, measurable as a luminescent signal. Compounds that cause an elevation in this signal are considered candidates for 1700022I11Rik Activators and are selected for further validation.
Post-screening, candidate activators undergo a battery of confirmatory tests to ensure that the luminescent increase corresponds to an actual elevation in 1700022I11Rik gene activity. Quantitative PCR (qPCR) is a pivotal technique in this phase, quantifying the mRNA levels of 1700022I11Rik. Complementing qPCR, Western blotting is used to detect and quantify the protein translated from the mRNA. This step confirms that the observed increase in mRNA results in a proportional synthesis of the protein and also sheds light on whether the activator affects protein stability or drives post-translational modifications. These methods together provide a quantitative and qualitative evaluation of the activator's influence on gene and protein expression levels, yielding a comprehensive understanding of the activator's effect on 1700022I11Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which phosphorylates a wide range of cellular targets. If the C9orf131 homolog is regulated by PKC-mediated phosphorylation, PMA could enhance its functional activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent protein kinases and phosphatases, which could modify the C9orf131 homolog if it is sensitive to calcium signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to activate intracellular signaling pathways, including those mediated by PI3K/Akt. If the C9orf131 homolog is a downstream effector in this pathway, its activity could be indirectly enhanced by such signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits a range of kinases and has been shown to have effects on the MAPK pathway. If the C9orf131 homolog is downstream of this pathway, EGCG could indirectly enhance its activity by modulating the pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that modulates the PI3K/Akt signaling pathway. If the C9orf131 homolog functions downstream of PI3K/Akt and is negatively regulated by it, inhibition by LY294002 could relieve this negative regulation and enhance the activity of the C9orf131 homolog. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could shift the balance of MAPK signaling. If the C9orf131 homolog is involved in a signaling branch that is regulated by p38 MAPK, then inhibition by SB203580 could indirectly enhance the activity of the C9orf131 homolog by modulating the pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which affects the PI3K/Akt pathway. Similar to LY294002, if the C9orf131 homolog is negatively regulated by PI3K/Akt, Wortmannin could enhance the activity of the C9orf131 homolog by inhibiting this negative regulation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. If the C9orf131 homolog is calcium-sensitive, this could lead to its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore, like ionomycin, and it increases intracellular calcium concentration. If the C9orf131 homolog is regulated by calcium-dependent mechanisms, A23187 could enhance its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. If there are kinases that negatively regulate the C9orf131 homolog, inhibition by staurosporine could lift this regulation and thereby enhance the activity of the C9orf131 homolog. | ||||||